Figure 7.
Dose-escalating regimen of OBP-301
OBP-301 was administered by intratumoral injection using ultrasound guidance. Each patient received an OBP-301 treatment within 14 days and automatically entered the follow-up period for up to 12 weeks after the last injection. Each patient returned for follow-up visits each week during the first month after the last injection, and then every 4 weeks until the end of the follow-up period of each phase.